Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 231

1.

Effect of valsartan on left ventricular anatomy and systolic function and aortic elasticity.

Khaodhiar L, Brennan AM, Lima C, Chan JL, Mantzoros CS, Manning WJ, Danias PG, Veves A.

Metabolism. 2009 May;58(5):682-8. doi: 10.1016/j.metabol.2009.01.009.

PMID:
19375592
2.

Valsartan improves resting skin blood flow in type 2 diabetic patients and reduces poly(adenosine diphosphate-ribose) polymerase activation.

Shrikhande G, Khaodhiar L, Scali S, Lima C, Hubbard M, Dudley K, Ganda O, Ferran C, Veves A.

J Vasc Surg. 2006 Apr;43(4):760-70; discussion 770-1.

3.

The effect of valsartan on regression of left ventricular hypertrophy in type 2 diabetic patients.

Suzuki K, Kato K, Soda S, Kamimura T, Aizawa Y.

Diabetes Obes Metab. 2004 May;6(3):195-9.

PMID:
15056127
4.

Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering.

Karalliedde J, Smith A, DeAngelis L, Mirenda V, Kandra A, Botha J, Ferber P, Viberti G.

Hypertension. 2008 Jun;51(6):1617-23. doi: 10.1161/HYPERTENSIONAHA.108.111674. Epub 2008 Apr 21.

5.

Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients.

Savoia C, Touyz RM, Volpe M, Schiffrin EL.

Hypertension. 2007 Feb;49(2):341-6. Epub 2006 Dec 11.

6.
7.
8.

Effects of the angiotensin II type 1 receptor antagonist valsartan on the expression of superoxide dismutase in hypertensive patients.

Yang HY, Kao PF, Chen TH, Tomlinson B, Ko WC, Chan P.

J Clin Pharmacol. 2007 Mar;47(3):397-403.

PMID:
17322151
9.

Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study.

Li PK, Leung CB, Chow KM, Cheng YL, Fung SK, Mak SK, Tang AW, Wong TY, Yung CY, Yung JC, Yu AW, Szeto CC; HKVIN Study Group.

Am J Kidney Dis. 2006 May;47(5):751-60.

PMID:
16632013
10.

The effect of valsartan on left ventricular myocardial functions in hypertensive patients with left ventricular hypertrophy.

Kucukler N, Kurt IH, Topaloglu C, Gurbuz S, Yalcin F.

J Cardiovasc Med (Hagerstown). 2012 Mar;13(3):181-6. doi: 10.2459/JCM.0b013e3283511f00.

PMID:
22306782
11.

Long-term effects of angiotensin II receptor blockade with valsartan on carotid arterial stiffness and hemodynamic alterations in patients with essential hypertension.

Okura T, Watanabe S, Kurata M, Koresawa M, Irita J, Enomoto D, Jotoku M, Miyoshi K, Fukuoka T, Higaki J.

Clin Exp Hypertens. 2008 Jul;30(5):415-22. doi: 10.1080/10641960802279108.

PMID:
18633763
12.

[Valsartan in patients with arterial hypertension and type 2 diabetes mellitus. The lapaval study].

Rodríguez Pérez JC, Novoa Novoa J, Caballero A, Anabitarte A, Plaza C, Palop L, Rodríguez Esparragón F.

Nefrologia. 2005;25(5):500-8. Spanish.

13.
14.

Effect of raloxifene on aortic elasticity in healthy postmenopausal women.

Tritos NA, Goepfert L, Kissinger KV, Katsimaglis G, Manning WJ, Danias PG.

Am Heart J. 2005 Dec;150(6):1212.

PMID:
16338260
15.

Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.

Miyajima K, Minatoguchi S, Ito Y, Hukunishi M, Matsuno Y, Kakami M, Kawasaki M, Nishigaki K, Takemura G, Fujiwara H.

Hypertens Res. 2007 Apr;30(4):307-13.

PMID:
17541209
16.
17.

Beneficial effects of valsartan in asymptomatic individuals with vascular or cardiac abnormalities: the DETECTIV Pilot Study.

Duprez DA, Florea ND, Jones K, Cohn JN.

J Am Coll Cardiol. 2007 Aug 28;50(9):835-9. Epub 2007 Aug 13.

18.

Renoprotective effects of low-dose valsartan in type 2 diabetic patients with diabetic nephropathy.

Suzuki K, Souda S, Ikarashi T, Kaneko S, Nakagawa O, Aizawa Y.

Diabetes Res Clin Pract. 2002 Sep;57(3):179-83.

PMID:
12126767
19.

Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial.

Anand IS, Rector TS, Kuskowski M, Thomas S, Holwerda NJ, Cohn JN.

Circ Heart Fail. 2008 May;1(1):34-42. doi: 10.1161/CIRCHEARTFAILURE.107.736975.

20.

Effects of valsartan on the progression of chronic renal insufficiency in patients with nondiabetic renal diseases.

Ishimitsu T, Kameda T, Akashiba A, Takahashi T, Ando N, Ohta S, Yoshii M, Inada H, Tsukada K, Minami J, Ono H, Matsuoka H.

Hypertens Res. 2005 Nov;28(11):865-70.

PMID:
16555574
Items per page

Supplemental Content

Write to the Help Desk